EcoDrugPlus

Proteasome 26s Subunit, Atpase 1a

Ensembl ID : ENSNBRG00000018521
Gene Symbol: PSMC1A
1 Cross references
279 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSNBRG00000015159
Gene Symbol: PSMD11
3 Cross references
207 Possible Orthologues:

Proteasome Subunit Alpha Type-1-Like

Ensembl ID : ENSNBRG00000015546
Gene Symbol: LOC102776922
3 Cross references
270 Possible Orthologues:

Proteasome Subunit Alpha Type-2-Like

Ensembl ID : ENSNBRG00000009619
Gene Symbol: LOC102777850
3 Cross references
269 Possible Orthologues:

Proteasome Subunit Alpha Type-3-Like

Ensembl ID : ENSNBRG00000021353
Gene Symbol: LOC102798504
3 Cross references
238 Possible Orthologues:

Proteasome Subunit Alpha Type-5-Like

Ensembl ID : ENSNBRG00000012888
Gene Symbol: LOC102796227
3 Cross references
211 Possible Orthologues:

Proteasome Subunit Alpha Type-6-Like

Ensembl ID : ENSNBRG00000018436
Gene Symbol: LOC102790081
3 Cross references
278 Possible Orthologues:

Proteasome Subunit Alpha Type-6-Like

Ensembl ID : ENSNBRG00000010002
Gene Symbol: LOC102776999
3 Cross references
244 Possible Orthologues:

Proteasome Subunit Alpha Type-7-Like

Ensembl ID : ENSNBRG00000013730
Gene Symbol: LOC102789190
3 Cross references
182 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSNBRG00000018149
Gene Symbol: PSMB11
3 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-1-A-Like

Ensembl ID : ENSNBRG00000004136
Gene Symbol: LOC102775570
3 Cross references
217 Possible Orthologues:

Proteasome Subunit Beta Type-2-Like

Ensembl ID : ENSNBRG00000013797
Gene Symbol: LOC102775732
3 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).